LivaNova plc buy DocProfit
Start price
28.01.20
/
50%
€62.50
Target price
04.11.21
€100.00
Performance (%)
-34.40%
End price
09.11.20
€41.00
Summary
This prediction ended on 09.11.20 with a price of €41.00. The BUY prediction by DocProfit for LivaNova plc performed very badly with a performance of -34.40%. DocProfit has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| LivaNova plc | -4.950% | -4.950% | 11.111% | -29.927% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
Comments by DocProfit for this prediction
In the thread LivaNova plc diskutieren
Buy mit Kursziel 100,0
Strong expected performance in Cardiovascular Segment. Upside potential through treatment of Corona Virus with Extracorporeal Life Support. LivaNova is well positioned for that.
LivaNova is a leader in Extra-Corporeal Membrane Oxygenation. A Theraphy that has established itself during Swineflue, Birdflue, SARS, MERS in the past. Well positioned as an Italian manufacturer the current Corona Epidemic will boost LivaNovas profits.